• Vetiranary Medicine
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

President Obama, FDA employ new strategies against drug shortages

January 1, 2012
Rachael Zimlich, BSN, RN

National Report - Atropine sulfate has just been added to the list of medically necessary veterinary drugs in short supply, reports the U.S. Food and Drug Administration (FDA).

NATIONAL REPORT — Atropine sulfate has just been added to the list of medically necessary veterinary drugs in short supply, reports the U.S. Food and Drug Administration (FDA).

Manufactured by Sparhawk Laboratories, the drug treats insecticide poisonings. The shortage has been cause by manufacturing delays.

Bert Hughes, president and chief executive officer of Sparhawk says the shortage came after FDA notified the company it would now consider atropine sulfate a new animal drug. The new classification requires Sparhawk to obtain a medically necessary waiver to import the drug's active ingredient.

Advertisement

The process to complete the waiver was lengthy, but Hughes says FDA helped the company through the process. He is now working with FDA on a new waiver for another importation of the drug's active ingredient so the company can manufacture additional supplies.

"I think as long as its in short supply, it appears to me that we can request the medically necessary waiver and FDA will work with us," Hughes explains.

FDA's efforts to help Sparhawk mitigate the shortage came on the heels of a new executive order by President Barack Obama targeting human-drug shortages.

Drug shortages tripled from 61 in 2005 to 178 in 2010, FDA says, with sterile injectables making up the bulk of those shortages (80 percent) in the human medical market. Oncology drugs (28 percent) were next, followed by antibiotics (13 percent) and electrolyte/nutritional drugs (11 percent). FDA helped prevent 38 drug shortages in 2010 and 99 so far in 2011, according to the agency's review of medical product shortages.

In an executive order signed Oct. 31, Obama directs FDA to take more action in preventing and reducing drug shortages and protecting consumers from price gouging.

Previously, FDA could only require drug manufacturers to disclose critical drug discontinuations when the drug is available through a sole manufacturer. But the President's executive order allows FDA to take additional steps, like requiring drug makers to provide more notice of manufacturing discontinuances or other actions that could lead to shortages. The order also expands FDA's ability to review new manufacturing sites, drug suppliers and manufacturing changes to prevent shortages.

In addition to the executive order, the Obama administration also sent a letter to drug manufacturers reminding them of their responsibility to report discontinuations of certain drugs to FDA and encouraging them to voluntarily disclose shortages to FDA in cases where disclosure is not required by law. Obama also increased staffing resources for FDA's Drug Shortages Program and has thrown support behind pending bipartisan legislation that would require all prescription drug shortages to be disclosed and give FDA new enforcement authority.

Related Content:

Medical
UC Davis oral surgeons repair kitten’s severe cleft palate
UC Davis oral surgeons repair kitten’s severe cleft palate
Tips and tricks for diagnosing canine osteoarthritis early
Tips and tricks for diagnosing canine osteoarthritis early
Performing surgery on dogs with GDV
Performing surgery on dogs with GDV

Advertisement

Latest News

Spectrum of care: protocols to support pet owners’ budgets

How to support women while still running a successful business

The Vets expands to Raleigh, NC

Two pups find their forever homes while at Fetch Charlotte

View More Latest News
Advertisement